` HEPA (Hepion Pharmaceuticals Inc) vs S&P 500 Comparison - Alpha Spread

HEPA
vs
S&P 500

Over the past 12 months, HEPA has underperformed S&P 500, delivering a return of -100% compared to the S&P 500's +17% growth.

Stocks Performance
HEPA vs S&P 500

Loading
HEPA
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
HEPA vs S&P 500

Loading
HEPA
S&P 500
Difference
www.alphaspread.com

Performance By Year
HEPA vs S&P 500

Loading
HEPA
S&P 500
Add Stock

Competitors Performance
Hepion Pharmaceuticals Inc vs Peers

S&P 500
HEPA
LLY
JNJ
NOVO B
ROG
Add Stock

Hepion Pharmaceuticals Inc
Glance View

Market Cap
702.7k USD
Industry
Pharmaceuticals

Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. The company is headquartered in Edison, New Jersey and currently employs 20 full-time employees. The company went IPO on 2014-02-07. The firm is focused on the development of drug therapy for treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma (HCC) associated with non-alcoholic steatohepatitis (NASH), viral hepatitis and other liver diseases. The Company’s cyclophilin inhibitor, CRV431, offer benefits to address these multiple complex pathologies. CRV431 is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease. The firm has created an AI platform, called AI-POWR, which stands for Artificial Intelligence Precision Medicine Omics World database access and Response and clinical outcomes. The platform helps to identify which NASH patients will best respond to CRV431, potentially shortening development timelines and increasing the delta between placebo and treatment groups.

HEPA Intrinsic Value
Not Available
Back to Top